InsiderTrades

Form 4 for RNAC Cartesian Therapeutics, Inc.

Accepted 2023-11-15 00:00:00 ET · period of report 2023-11-13 · accession 0001062993-23-020921 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-11-15 2023-11-13 RNAC Kalayoglu Murat Dir, 10% A - Grant $0.00 +257.7K 257.7K New $0
DI 2023-11-15 2023-11-13 RNAC Kalayoglu Murat Dir, 10% J - Other $0.00 +3.30M 3.30M New $0
DI 2023-11-15 2023-11-13 RNAC Kalayoglu Murat Dir, 10% P - Purchase $249,999.98 +619.63 619.63 New +$154.91M
D 2023-11-15 2023-11-13 RNAC Kalayoglu Murat Dir, 10% A - Grant — +14.8K 14.8K New —
DI 2023-11-15 2023-11-13 RNAC Kalayoglu Murat Dir, 10% J - Other — +189.1K 189.1K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-11-13 A A 257,739 $0.00 257,739 D by trust — — (F1) On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. (F2) Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.
2 Common Common Stock 2023-11-13 J A 3,303,699 $0.00 3,303,699 I — — (F1) On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.
3 Derivative Series A Non-Voting Convertible Preferred Stock 2023-11-13 P A 619.63 $249,999.98 619.63 I — · — to — 619,627 Common Stock (F4) On November 13, 2023, the Trust entered into a Securities Purchase Agreement with the Company and other investors, pursuant to which the Trust agreed to acquire 619.627 shares of Series A Preferred Stock. (F3) Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
4 Derivative Series A Non-Voting Convertible Preferred Stock 2023-11-13 A A 14,755.61 — 14,755.61 D by trust — · — to — 14,755,609 Common Stock (F1) On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. (F2) Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. (F3) Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.
5 Derivative Series A Non-Voting Convertible Preferred Stock 2023-11-13 J A 189,136.77 — 189,136.77 I by trust — · — to — 189,136,767 Common Stock (F1) On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. (F2) Shares are held in a trust (the "Trust") for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust. (F3) Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.